Treatment and outcomes of Enterococcus faecium bloodstream infections in solid organ transplant recipients

Authors

Nicholas J. Mercuro, Henry Ford HealthFollow
Christian Gill, Henry Ford HealthFollow
Rachel M. Kenney, Henry Ford HealthFollow
George Alangaden, Henry Ford HealthFollow
Susan L. Davis, Henry Ford HealthFollow

Recommended Citation

Mercuro NJ, Gill CM, Kenney RM, Alangaden GJ, and Davis SL. Treatment and outcomes of Enterococcus faecium bloodstream infections in solid organ transplant recipients. Transpl Infect Dis 2020.

Document Type

Article

Publication Date

1-30-2020

Publication Title

Transplant infectious disease

Abstract

The Centers for Disease Control and Prevention estimates that resistant enterococci are responsible for 20,000 infections and over 1,000 deaths in the United States each year, representing 8% of nosocomial bloodstream infections.(1,2) Solid organ transplant (SOT) recipients, particularly liver, are among the populations at greatest risk of disease caused by resistant enterococci.(3,4) Colonization with vancomycin resistant-Enterococcus (VRE) is present in about 15% of patients with of abdominal transplant recipients, or on waiting lists.

PubMed ID

31997476

ePublication

ePub ahead of print

First Page

13251

Last Page

13251